Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Halofuginone - Processa Pharmaceuticals

Next Previous
Drug Profile

Halofuginone - Processa Pharmaceuticals

Alternative Names: Halofuginone hydrobromide; HT-100; PCS-100; Stenorol™; Tempostatin™

Latest Information Update: 28 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Collgard Biopharmaceuticals
  • Developer Akashi Therapeutics; Collgard Biopharmaceuticals
  • Class Antifibrotics; Antineoplastics; Hepatoprotectants; Piperidines; Quinazolinones; Skin disorder therapies; Small molecules; Urologics; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Collagen type I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Discontinued Bladder cancer; Cancer; Coronary artery restenosis; Hepatic fibrosis; Kidney disorders; Renal fibrosis; Scleroderma

Most Recent Events

  • 28 Sep 2022 Halofuginone is still in phase II trials for Duchenne muscular dystrophy in USA (Akashi Therapeutics pipeline, September 2022)
  • 05 Nov 2019 Halofuginone is sub-licensed to Processa Pharmaceuticals worldwide
  • 21 Apr 2017 Akashi Therapeutics terminates the HALO-DMD-03 phase II trial for Duchenne muscular dystrophy in USA (NCT02525302)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top